VTVT Stock — vTv Therapeutics Inc.: Metrics

Market overview

2 metrics

Share price

$33.40

Market cap

$131.83M

Price action

19 metrics

Price change (1W)

-5.8%

Price change (30D)

-1.4%

Price change (3M)

-3.2%

Price change (6M)

-7.8%

Price change (YTD)

-20.1%

Price change (1Y)

+96.7%

Trailing year

Price change (5Y)

—

52-week high

$42.72

52-week low

$18.31

Change from 52-week high

-25.2%

Change from 52-week low

+74.5%

Annualized volatility

72.7%

Beta

1.1

RSI (14D)

45.1

Price vs SMA 50

-3.7%

Price vs SMA 200

-7.0%

Avg volume (3M)

74,237

Relative volume

0.7

Average dollar volume

$2.46M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

3.95M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

3.5×

reciprocal yield 28.8%

P / book

1.6

reciprocal yield 61.5%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-3.7%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

—

Profitability

9 metrics

Gross margin

—

Operating margin

-25.1%

Trailing 12 months

Net margin

-12.9%

Gross profit (TTM)

—

Operating profit (TTM)

−$9.25M

Net income (TTM)

−$4.76M

Trailing 12 months

Diluted EPS (TTM)

—

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

—

Growth

11 metrics

Revenue growth YoY

-100.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$36.84M

Trailing 12 months

EPS growth YoY

—

Shares change YoY

—

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-6.0%

Return on assets

-5.4%

Debt / equity

—

Current ratio

12.5

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

12.5

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Cash & equivalents

$86.64M

Total assets

$87.59M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$16.76M

Capital expenditures (TTM)

—

R&D (TTM)

$28.68M

SG&A (TTM)

—

Stock compensation (TTM)

$5.15M

R&D / revenue

77.8%

Stock compensation / revenue

14.0%

Ownership (13F)

3 metrics

13F filers

45

13F filer change QoQ

+10

Institutional ownership

40.6%

Short interest

3 metrics

Short interest

4.2%

Latest settlement · 1.6 days to cover

Days to cover

1.6d

Short-squeeze score

58 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

VTVT · vTv Therapeutics Inc.

VTVT metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search